Entera Bio Shares Soar 212% in 2 Years Amidst Executive Pay Disclosures

TL;DR

**ENTX's stock is on a tear, up 212% in two years, making executive compensation disclosures a must-read for anyone betting on continued growth.**

AI Summary

Entera Bio Ltd.'s DEF 14A filing, dated June 5, 2025, primarily details executive compensation and its relationship to company performance, specifically focusing on 'compensation actually paid' (CAP) to its Principal Executive Officer (PEO) and Non-PEO NEOs. The filing indicates that the per share closing price for Entera Bio's Ordinary Shares significantly increased from $0.73 on December 31, 2022, to $0.60 on December 31, 2023, and then to $2.28 on December 31, 2024, representing a substantial increase in shareholder value over the two-year period. The company reported net losses for the applicable fiscal years, as reflected in its audited consolidated financial statements, though specific dollar amounts for net loss are not provided in this excerpt. No dividends were paid on share or option awards for any periods presented, meaning the shareholder return is purely from stock price appreciation. The valuation assumptions for equity award adjustments, computed in accordance with FASB ASC Topic 718, did not materially differ from those disclosed at the time of grant, suggesting consistent accounting practices. The filing also clarifies that no equity awards were cancelled due to a failure to meet vesting conditions, indicating a stable environment for executive incentives.

Why It Matters

This filing is crucial for investors as it provides transparency into how executive compensation at Entera Bio Ltd. (ENTX) aligns with shareholder returns, especially given the significant 212% increase in share price from $0.73 to $2.28 between December 31, 2022, and December 31, 2024. Understanding the 'compensation actually paid' (CAP) metrics helps investors evaluate management's incentives and performance in a competitive biotech landscape. For employees, it offers insight into the company's compensation philosophy, while customers and the broader market can infer the company's financial health and strategic focus through its executive reward structures. The lack of dividends suggests a reinvestment strategy, which is common for growth-oriented biotech firms.

Risk Assessment

Risk Level: medium — While the stock price has seen significant appreciation, the filing mentions 'net loss is reflected as reported in our audited consolidated financial statements for the applicable fiscal year,' without providing specific dollar amounts. This lack of detail on profitability, despite stock gains, introduces a medium risk as sustained losses could eventually impact long-term viability and shareholder value. The reliance on stock appreciation for shareholder return, with no dividends paid, also indicates a growth-stage company with inherent volatility.

Analyst Insight

Investors should scrutinize Entera Bio's full financial statements to understand the magnitude of the reported net losses and assess the sustainability of its growth trajectory. Given the substantial stock price increase from $0.73 to $2.28, consider if the current valuation is justified by underlying business fundamentals and future pipeline potential, rather than solely relying on past stock performance.

Financial Highlights

total Assets

Not Disclosed

cash Position

Not Disclosed

total Debt

Not Disclosed

Executive Compensation

Key Numbers

• $2.28 — Ordinary Share closing price (on December 31, 2024, up from $0.73 on December 31, 2022)
• $0.60 — Ordinary Share closing price (on December 31, 2023)
• $0.73 — Ordinary Share closing price (on December 31, 2022)
• 212% — Stock price increase (from December 31, 2022, to December 31, 2024)

Key Players & Entities

• Entera Bio Ltd. (company) — filer of DEF 14A
• Hillel Galitzer (person) — Non-PEO NEO
• Dana Yaacov-Garbeli (person) — Non-PEO NEO
• FASB ASC Topic 718 (regulator) — accounting standard for equity award valuation
• SEC (regulator) — regulator of DEF 14A filings
• $100 (dollar_amount) — assumed initial investment for TSR calculation

FAQ

Risk Factors

• Net Losses [medium — financial]: The company has reported net losses for the applicable fiscal years as reflected in its audited consolidated financial statements. Specific dollar amounts for net loss are not provided in this excerpt, but the continued losses indicate ongoing operational costs exceeding revenue.
• Stock Price Volatility [medium — market]: The stock price experienced significant fluctuations, closing at $0.73 on December 31, 2022, dropping to $0.60 on December 31, 2023, before surging to $2.28 on December 31, 2024. This volatility, despite the recent upward trend, presents a risk for investors and can impact executive compensation tied to stock performance.
• Executive Compensation Reporting [low — operational]: The DEF 14A filing focuses on 'compensation actually paid' which is an average and may not reflect actual compensation earned or received by executives. This reporting methodology could obscure the true compensation picture for individual executives.

Industry Context

Entera Bio Ltd. operates in the biotechnology sector, specifically focusing on biological products. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on innovation and clinical trial success to drive value, with a competitive landscape that includes both large pharmaceutical companies and smaller, specialized biotech firms.

Regulatory Implications

As a biotechnology company, Entera Bio Ltd. is subject to stringent regulatory oversight from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP), clinical trial regulations, and drug approval processes are critical. Any failure to adhere to these regulations can result in significant delays, fines, or product rejection, impacting financial performance and market access.

What Investors Should Do

1. Review the full audited financial statements for detailed net loss figures and operational expenses.
2. Investigate the drivers behind the significant stock price increase from December 2023 to December 2024.
3. Analyze the 'compensation actually paid' methodology in detail to understand executive incentives.

Key Dates

• 2022-12-31: Ordinary Share closing price — Represents the baseline stock price for calculating total shareholder return and executive compensation performance over the subsequent years.
• 2023-12-31: Ordinary Share closing price — Shows a decrease in stock price from the previous year, potentially impacting executive compensation metrics if tied to short-term performance.
• 2024-12-31: Ordinary Share closing price — Indicates a substantial increase in stock price, demonstrating significant shareholder value appreciation over the two-year period.
• 2025-06-05: DEF 14A Filing — Provides details on executive compensation, company performance metrics, and other governance information for the fiscal year.

Glossary

DEF 14A

A proxy statement filing required by the SEC for publicly traded companies, typically detailing executive compensation, director information, and other corporate governance matters. (This document provides the primary source of information for executive compensation and company performance metrics discussed in the filing.)

Compensation Actually Paid (CAP)

A metric mandated by the SEC that requires companies to report compensation paid to their top executives, adjusted to reflect the impact of stock price changes and other factors. (This filing uses CAP to report executive compensation, highlighting the difference between compensation paid and compensation earned.)

PEO

Principal Executive Officer, the highest-ranking executive in a company. (The filing specifically details compensation for the PEO and compares it to other named executive officers.)

Non-PEO NEO

Non-Principal Executive Officer Named Executive Officer. These are other top executives of the company whose compensation is disclosed. (The filing includes compensation information for these executives, Hillel Galitzer and Dana Yaacov-Garbeli.)

FASB ASC Topic 718

Accounting Standards Codification Topic 718, which provides guidance on accounting for stock-based compensation. (This standard is used by Entera Bio Ltd. to value equity awards and calculate adjustments for 'compensation actually paid'.)

Total Shareholder Return (TSR)

A measure of the total return an investor receives from holding a stock, including stock price appreciation and reinvested dividends. (The filing discusses TSR, noting that all shareholder return is derived from stock price appreciation as no dividends were paid.)

Year-Over-Year Comparison

This DEF 14A filing highlights a significant positive shift in shareholder value, with the Ordinary Share closing price increasing from $0.60 on December 31, 2023, to $2.28 on December 31, 2024. This contrasts with the previous year's trend where the price decreased from $0.73 to $0.60. While the filing indicates net losses for the fiscal years, the substantial stock appreciation suggests that investors are looking beyond current profitability towards future potential, a key performance indicator for the biotechnology sector.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 5, 2025 by Hillel Galitzer regarding Entera Bio Ltd. (ENTX).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR